Search This Blog

Friday, March 8, 2019

OxyContin maker Purdue Pharma loses bid to delay opioid epidemic trial

OxyContin maker Purdue Pharma LP and two other drugmakers on Friday lost a bid to delay a landmark trial set for May in a multibillion-dollar lawsuit by Oklahoma’s attorney general accusing them of helping fuel an opioid abuse and overdose epidemic in the state.

Cleveland County District Judge Thad Balkman’s decision was a win for the state, even as one of the lawyers for the state said Purdue had “threatened” to file for bankruptcy rather than face the first trial to result from around 2,000 lawsuits nationally.
“This case needs to get to trial because people are dying every day,” Reggie Whitten, the lawyer for the state, said during a hearing in Norman, Oklahoma.
Reuters, citing people familiar with the matter, on Monday reported that Stamford, Connecticut-based Purdue, owned by members of the wealthy Sackler family, was exploring filing for Chapter 11 bankruptcy protection. Doing so would allow it to address potential legal liabilities while halting the cases.
Eric Pinker, Purdue’s lawyer, made no mention of a potential bankruptcy while arguing that the May 28 trial in the lawsuit brought by Oklahoma Attorney General Mike Hunter against it, Johnson & Johnson and Teva Pharmaceutical Industries Ltd should be delayed.
He said delaying the trial to Sept. 16 was necessary because the state belatedly turned over 1.6 million pages of records critical to Purdue’s defense. “This case is not at a posture where it can fairly and fully go to trial in May of this year,” Pinker said.
But the judge said the drugmakers had not established the state’s actions had prejudiced them.
Purdue in a statement said it “categorically” denies that the ruling will affect whether it files for bankruptcy. Purdue said it was “looking at all of its options” but had made no decisions.
Opioids, including prescription painkillers, heroin and fentanyl, were involved in a record 47,600 overdose deaths in 2017, according to the U.S. Centers for Disease Control and Prevention.
The epidemic has prompted lawsuits by state and local governments accusing Purdue and other drugmakers of contributing to the crisis through deceptive marketing that downplayed the risks of addictive opioids.
The companies deny wrongdoing, noting their drugs carried warning labels and pointing to others factors behind the epidemic.
More than 1,600 lawsuits have been consolidated before a federal judge in Ohio, who has pushed for a settlement ahead of the trial before him in October. Other cases, including Oklahoma’s, are pending in state courts.

Medtronic to buy back additional $6B of stock

The board of Medtronic (NYSE:MDT) has authorized the repurchase of an additional $6B of its common stock. It had $1.3B remaining under its June 2017 authorization at the end of the last fiscal quarter.

Healthcare fell in line with weak overall job growth in February

Despite healthcare’s strong kickoff to 2019, the industry’s job growth fell 50% in February.
The healthcare sector made 20,800 new hires last month, according to the U.S. Bureau of Labor Statistics’ February jobs report. That’s compared with January’s 41,600 new hires despite the government shutdown that lasted almost the entire month.
February was a weak month for overall job growth, with total non-farm jobs growing by just 20,000. By comparison, the overall job market made 311,000 new hires in January. The unemployment rate declined by 0.2% to 3.8% in February.
Healthcare hiring trailed that of professional and business services, which added 42,000 jobs last month, but beat out wholesale trade, which made just 10,900 new hires. Construction shed 31,000 jobs during the month.
As is typically the case, ambulatory hiring dominated the healthcare industry in February, comprising three-quarters of new hires. Healthcare’s ambulatory sector added 15,500 new jobs last month, down from 22,100 in January. With the ambulatory sector, outpatient care centers added 4,900 new jobs, while home health care added 4,700. Physicians’ offices made 3,100 new hires, while dentists made 2,600.
Hospitals added just 4,200 new jobs last month, down 78% from January, when they added 18,800. It was also a weak month for nursing and residential care facility hiring. That sector added just 1,100 jobs. Within it, community care facilities for the elderly shed 500 jobs.

Off-the-shelf approaches keep cell therapy investors keen

Late-stage and commercially available cell therapies have a had a rough time of it. Novartis’s Kymriah is mired in manufacturing problems, while Kite and Juno are causing their acquirers all sorts of headaches.
Nevertheless, the rush to back version 2.0 of the technology continues, as evidenced by continued support for cell therapy company flotations this year: think Poseida, TCR2 and just last week Precision Biosciences. Like Allogene, whose IPO raised over $300m last year, all the new entrants are looking at allogeneic approaches that reduce the complexity of adoptive cell therapy.
Still, only Precision has this as its primary goal. This company boasts a gene-editing technology that uses arcus nucleases and hopes to rival Allogene/Cellectis’s meganucleases and the likes of Crispr/Cas9.
Allogeneic cell therapies require gene-editing to eliminate the threat of graft-versus-host disease, typically by editing out the T cells’ endogenous T-cell receptors. The jury is still out on what the most accurate and efficient technology is, not to mention the fact that their respective intellectual property positions are unclear.
In a strange chain of events, rights to Precision’s technology and lead asset, PBCAR0191, have ended up with Servier. This is particularly noteworthy as the French company already has rights to the most advanced allogeneic CAR-T therapy, Cellectis/Allogene’s UCART19, through a deal dating back to five years ago.
PBCAR0191 was one of six CAR-T assets that were first licensed by Precision to Baxalta, a company with no cell therapy expertise, when that group was already in the process of being acquired by Shire. Once in Shire’s hands, it was divested along with legacy oncology assets to Servier, just before Shire itself was bought by Takeda (Shire taunts Takeda with oncology sale, April 16, 2018).
Precision filed last week to raise $100m in an IPO whose price has yet to be determined. Its allogeneic CARs target antigens that are well known in haematology: CD19, CD20, BCMA and CLL-1.
Poseida’s splash
Targeting BCMA has recently become an extremely crowded field, and the players here include Poseida, which made a splash at the JP Morgan conference by announcing plans to raise $115m in a flotation. However, things have gone quiet since, and the proposed offering has still not been priced.
Poseida calls its gene-editing technology Cas-Clover, and this appears to be a variation of Crispr/Cas9. Its most advanced allogeneic asset is P-BCMA-ALLO1, but this will not enter the clinic until late 2019 or 2020.
Its lead is an autologous BCMA-directed CAR, P-BCMA-101, which is in phase I and which Poseida has put on an ambitious US approval timeframe, revealing at Ash that it would be filed next year. This asset uses the virus-free Piggybac system – similar to Ziopharm’s Sleeping Beauty – to transduce the T cells without using a viral vector, and the same iCasp9/rimiducid-based safety switch that Bellicum claims is its own.
Poseida has licensed Johnson & Johnson’s Centyrins technology to develop CAR-T binding domains that are not based on antibody motifs. A separate J&J tie-up, with Poseida’s parent company, Transposagen, and covering the joint development of CAR-T therapies, was terminated two years ago.
TCR2 or just old-school CAR-T?
The final member of the new entrant trio, TCR2 Therapeutics, has already pulled off a Nasdaq listing, raising $75m last month and seeing its stock climb 28% since, resulting in a $450m market cap.
TCR2 is developing what it calls TRuC-T cell constructs. These look like a cross between CARs and engineered T-cell receptors (TCRs), being structurally similar to the latter but using a different region for binding the antigen, and the company boasts of being able to target irrespectively of patients’ HLA type.
But this is precisely what CAR-T itself can do, and TCR2 is not claiming to target intracellular antigens – the main theoretical advantage of an engineered TCR approach. Indeed, its targets are mesothelin, Muc16, CD19 and CD22 – typical extracellular proteins that a CAR can hit. TCR2’s selling point seems to be the ability to “harness the entire TCR signalling complex”.
The group has not revealed its allogeneic strategy, and remarkably it has yet to start a single human trial: its autologous lead, TC-210, will only enter clinical trials this year. The ability of a company to reach a half-billion dollar valuation without any clinical data speaks volumes about the market’s continuing fascination with cell therapies.

Why do doctors underdiagnose these 3 conditions in women?

According to some reports, women also face discrimination as patients. Sometimes, their doctors fail to diagnose conditions they are struggling with, or offer them the wrong diagnosis and consequently, the wrong kind of therapy.
In this Spotlight feature, we will look at some of the conditions that doctors underdiagnosed in women and explore some of the possible reasons behind these lacks in medical care.

1. Endometriosis

One of the chronic conditions that many women struggle with for a long time before they manage to receive a correct diagnosis — if they ever do — is endometriosis.
woman in pain holding her abdomen
Women have to wait to get their endometriosis diagnosed for ‘a disturbingly long time.’
Endometriosis is a progressive gynecological condition, which doctors currently consider incurable. Endometriosis occurs when the type of tissue that usually only lines the uterus grows in other parts of the body. This can include the ovaries, fallopian tubes, urethra, but also the bowel, kidneys, and other organs.
Symptoms of this condition include debilitating pain in the pelvic area, as well other parts of the body, heavy and persistent menstrual bleeding, spotting between periods, pain during sex with vaginal penetration, nausea and vomiting, severe headaches, and persistent fatigue.
These symptoms can often have a severe impact on an individual’s quality of life, affecting their productivity, other aspects of their physical and mental health, and their relationships.
Estimates in the journal Fertility and Sterility indicate that 10–15 percent of women of reproductive age live with this condition, and 70 percent of women who experience chronic pelvic pain actually have endometriosis.
Researchers from the Endometriosis Association, which is an international research and advocacy organization, write, “The time from the onset of symptoms to diagnosis is disturbingly long.” Two-thirds of the people they spoke to begin to experience symptoms of endometriosis during adolescence. However, most of these people do not seek medical attention immediately, and once they do, it can take doctors 10–12 years to make a correct diagnosis.
Typically, doctors can only diagnose endometriosis by conducting a laparoscopy. This is a minor surgical procedure in which a doctor inserts a tiny camera into the abdomen to look for lesions and abnormalities.
A doctor may prescribe pain relief medication or hormonal therapy for the management of endometriosis, but since this condition is progressive, many people require multiple and regular surgeries to remove the abnormal tissue growth.

‘So validating to know I wasn’t weak or crazy’

One woman, aged 25, who spoke to Medical News Today, explained that she lived with severe endometriosis symptoms for years before she received a correct diagnosis.
Primarily, this was because both she, her family, and the doctors that she consulted, thought that her disabling symptoms were nothing more than “bad period pains,” or else they mistook them for other health problems.
“I thought it was totally normal to have excruciating pain and 10-day-long heavy periods,” she told us. “My mom, aunt, and grandmother all had the same experience, so I was always told ‘that’s just how it is for women in our family,'” she added.
I thought maybe I was weak and not able to handle the pain as well as other girls. Last year I was diagnosed with deep infiltrating endometriosis and finally had an explanation and, most importantly, a treatment plan. It was so validating to know I wasn’t weak or crazy, just dealing with a chronic condition.”
She also told us that her journey towards a diagnosis was difficult and long-winded. “I’ve gone through three [general practitioners] and two gynecologists in 2 years,” she explained. She added that because her condition affected several organs, she received many different — and incorrect — diagnoses before the doctors eventually identified the real issue.
“I have endometriosis on my bladder, urethra, kidneys, and bowel, so I wound up with many doctors saying ‘you have [irritable bowel syndrome]’ and ‘you have [pelvic inflammatory disease],’ when I knew this wasn’t the case.”

2. Coronary heart disease

Another health problem that doctors often fail to spot in women is coronary (or ischemic) heart disease (CHD). This disease occurs when the arteries that deliver oxygenated blood into the heart, so that the heart can pump it out to the other organs, become unable to “service” the heart effectively.
woman pressing her chest
Since researchers conduct most clinical trials in men, we still lack a clear idea of how heart disease manifests in women.
The symptoms of CHD vary from person to person, which can make the condition challenging for doctors to spot. However, more generally, symptoms also differ between men and women, and more women thus go undiagnosed until the condition becomes exacerbated.
The National Heart, Lung, and Blood Institute explain that symptoms can also vary between different types of CHD, and some people do not experience any symptoms at all. However, some common symptoms include angina (pressure in the chest area, especially during physical activity), neck pain, and fatigue.
They also state that “[h]eart disease is the leading cause of death for women,” and that women are more at risk than men of developing non-obstructive CHD. This condition can occur when the arteries that go into the heart abnormally tighten or are “squeezed” by the surrounding tissue.
Unlike obstructive CHD, which is more likely to be characterized by tell-tale chest pain, non-obstructive CHD is often “silent” and may go unnoticed for a long time.
Past research published in the BMJ has argued that doctors often miss CHD in women because of the different set of symptoms and because women themselves do not seek medical attention early on.
“Women may have more atypical symptoms than men — such as back pain, burning in the chest, abdominal discomfort, nausea, or fatigue — which makes the diagnosis more difficult,” the researchers write.
Moreover, they add that: “Women are less likely to seek medical help and tend to present late in the process of their disease. They are also less likely to have appropriate investigations, such as coronary angiography and, together with late presentation to hospital, this can delay the start of effective treatment.”

‘Research has focused primarily on men’

Specialists have been trying to find better ways of assessing and diagnosing women with heart problems, but they acknowledge there is still a long way to go in this respect.
One review, which appears in the journal Circulation Research, notes, “For the past 3 decades, dramatic declines in heart disease mortality for both men and women have been observed, especially in the [over] 65 years age group.”
“However,” its authors add, “recent data suggest stagnation in the improvements in incidence and mortality of coronary heart disease, specifically among younger women.”
But why is this the case? The study authors argue that it may all be down to the underrepresentation of female populations in clinical studies for heart and vascular problems. They write:
For many decades, [cardiovascular disease] research has focused primarily on men, thus leading to an underappreciation of sex differences from an etiologic, diagnostic, and therapeutic perspective. As long as women are underrepresented in clinical trials, we will continue to lack data to make accurate clinical decisions on 51 [percent] of the world’s population.”

3. Attention deficit/hyperactivity disorder

Women do not just miss out on physical health diagnoses; this problem also extends to other conditions, such as behavioral conditions, and more specifically, attention deficit/hyperactivity disorder (ADHD).
two girls in tutus holding rag dolls
Girls and women with ADHD may never receive a diagnosis.
The National Institute of Mental Health defineADHD as “a brain disorder marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development.”
Typically, doctors see ADHD as a problem specific to childhood, and the Centers for Disease Control and Prevention (CDC) note that in 2016 — the latest year for which data are available — around 6.1 million children in the United States had received an ADHD diagnosis.
Furthermore, according to the Anxiety and Depression Association of America, while approximately 60 percent of children with ADHD in the U.S. continue to experience the symptoms of this condition as adults, less than 20 percent of adults with ADHD receive the correct diagnosis.
If adults, in general, struggle to receive a diagnosis, the situation is even worse in the case of women. Research has shown that both families and healthcare professionals are biased towards believing that boys and men are more likely to have ADHD, and they are more likely to ignore similar symptoms in girls and women.
In fact, some sources indicate that up to three-quarters of all women with ADHD never receive a diagnosis, and in the case of children, doctors diagnose fewer girls than boys with ADHD.
Moreover, girls have to wait longer than boys to receive a diagnosis of ADHD. While boys, on average, receive a diagnosis at age 7, girls have to wait until they reach the age of 12 to get the same clinical attention.

Some women think ‘it is too late’

In a review published in The Primary Care Companion for Central Nervous System Disorders, researchers explain that in boys and men, ADHD manifests as hyperactivity and impulsiveness; in girls and women, this condition takes a different guise. In women and girls, the primary symptom of ADHD is inattentiveness, which doctors may struggle to spot. Often doctors take this less seriously.
The same source also suggests that girls and women with ADHD may develop ways of masking their symptoms. Some may appear to have better coping strategies than boys and men with the same condition.
Also, because people with ADHD sometimes have other mental health problems, such as anxietydepression, and obsessive-compulsive disorder, the review authors point out that existing evidence indicates that doctors will much more eagerly diagnose women as living with a mental health condition, but deny them an ADHD diagnosis.
One woman — now in her 50s — who spoke to MNT told us that although she fits ADHD criteria and has lived with ADHD symptoms for a long time, she still has not received an official diagnosis.
“Therapists are pretty sure I have ADHD, the [national health services] still do not diagnose ADHD in adults and in particular women, and [only] direct you to do online tests,” she explained, adding:
[After] reading an article by a man in the United Kingdom that [said] it took years for him to get a diagnosis, I stopped worrying about it. It is too late to take medication for it at my age; as they say, [it would be like] shutting the stable door after the horse has bolted.”
Although medical systems across the globe have come a long way in terms of providing better quality care at an appropriate time, such accounts make one issue very apparent, namely that discrimination is still present in clinical research and health care. To fight it, we must all learn how to listen — really listen.

Livongo Health readies for IPO later this year

  • Chronic disease management startup Livongo Health has hired a trio of high-powered investment banks to help it prepare for an initial public offering as early as the third quarter of this year, The Wall Street Journal reports.
  • The company, which offers cloud-based glucose monitoring to diabetics via employer-based health plans, has engaged Morgan Stanley, Goldman Sachs and J.P. Morgan Chase to underwrite the IPO, which is expected to value the company at more than $1 billion, according to sources familiar with the dealings.
  • Founded in 2014, Livongo has raised $240 million in six funding rounds. The latest, in April 2018, captured $105 million led by Kinnevik AB and General Catalyst.

Digital health IPOs have been few and far between in recent years. Chinese fitness tracker Huami raised $110 million in a NYSE IPO in February 2018. Before that, the last IPO appears to have been iRhythm in 2016.
Livongo’s planned IPO comes as digital health funding hit a record high of $8.1 billion across 368 deals last year, up from $5.7 billion the previous year, according to Rock Health. A report by Mercom Capital Group put the haul even higher, at $9.5 billion through 698 deals.
Livongo has been readying itself for expansion. Last year, the Silicon Valley startup named former Cerner president Zane Burke its new CEO, replacing Glen Tullman, who assumed the title of executive chairman. Tullman previously served as CEO of EHR giant Allscripts. The company also elevated chief medical officer Jennifer Schneider to president, a position that will oversee activities ranging from data science and software engineering to marketing and clinical operations.
Livongo currently has more than 600 employers enrolled in its chronic disease management programs, which include cardiovascular diseases, weight loss and behavioral health issues in addition to diabetes. Customers include Express Scripts and CVS, as well as four of the top seven payers.
The company has also teamed up with Abbott to offer the devicemaker’s FreeStyle Libre Pro System to Livongo members with diabetes. The sensor, affixed to the back of the upper arm, reads glucose levels every 15 minutes to form a glycemic profile of the patient, including patterns and trends, that they can share with their doctor. The sensor is removed after 14 days.
In a December interview with MedTech Dive, Tullman said that Livongo’s 2018 revenue would more than double to about $61 million.
With some 30 million Americans diagnosed with diabetes, Livongo has lots of potential marketwise, though it also faces competition. Startups like Bigfoot Biomedical and Sweetch are also vying for a piece of the diabetes management pie, as well as a number of more established companies. For example, Roche bought digital diabetes management platform mySugr in 2017, and Apple is said to be developing noninvasive sensors that can monitor blood sugar and help diabetics manage their disease.

Sage duels with Marinus

With one positive trial for postpartum depression under its belt Sage Therapeutics will be keen to keep up the momentum when phase II results with SAGE-217 in bipolar depression read out in the next few months.
The primary endpoints of the Archway study are safety and tolerability, so the results are unlikely to move the needle on Sage shares, which have already increased by 67% since the start of the year.
But secondary endpoints include improvements in depression as measured by the HAM-D and MADRS scores, so success in this particular population would strengthen the case that SAGE-217, a first-in-class oral GABA modulator, differs from the competition.
Further differentiation could come from successive trials. The next big catalyst is phase III results in major depressive disorder (MDD), now expected in the fourth quarter or early 2020.This is where analysts see the most value for SAGE-217.
Success in MDD, alongside significantly derisking the project, would also go some way to justifying Sage’s $7.7bn market cap. This valuation could be further bolstered by the expected approval on March 19 of the group’s most advanced project, the IV GABA modulator Zulresso, on which the oral asset SAGE-217 is based.
For now SAGE-217 remains one the biggest projects in the CNS pipeline, but as anyone following the CNS sector knows midstage trials are one thing; the real test is delivering phase III success.
SELECTED KEY SAGE-217 TRIALS
StudyIndicationReadoutStatusTrial ID
ArchwayBipolar depressionH1 2019Phase IINCT03692910
MountainMajor depressive disorderQ4/2020Phase IIINCT03672175
RainforestInsomnia2020Phase IIINCT03771664
Depression trifecta
Sage’s direct competitor, Marinus, saw its stock spike on recent news that it was starting a pivotal trial of oral ganaxolone in children with a rare genetic form of epilepsy.
But the bulk of ganaxolone’s sellside consensus forecasts concern sales in postpartum depression. As investors now look to the two trials in this disorder due to read out in the first half, they will be keenly aware of the setbacks Marinus has already suffered.
The Magnolia trial, initially testing ganaxolone by 60-hour IV infusion, was delayed before reading out inconclusively in December, and in January the commercial opportunity was turned on its head by positive data from Sage’s SAGE-217. The trifecta of disappointments was completed last month when Marinus’s chief executive resigned.
Still, the two upcoming readouts, from the Amaryllis trial and part two of Magnolia, are important in determining how Marinus might proceed with pivotal development. The idea – at least until SAGE-217 scored – was that a non-hospital postpartum depression drug was needed to rival Sage’s IV Zulresso.
Amaryllis tests undisclosed oral ganaxolone doses, and while its clinicaltrials.gov entry cites a placebo-controlled design Marinus’s latest investor update said the efficacy endpoint would look at changes in HAM-D17 scores versus baseline. Interim data in December showed a 13.2-point HAM-D17 reduction at 28 days, which the company said supported its IV-to-oral approach.
Magnolia, meanwhile, could provide further evidence, thanks to its second part, which Marinus says tests an IV dose of shorter duration than 60 hours, followed by oral ganaxolone. However, clinicaltrials.gov sheds no light on this design, and calls Magnolia a trial of IV ganaxolone.
Leerink analysts reckon the pivotal path in postpartum depression could involve two similarly sized studies like Sage’s, and/or a partnering deal. However, given that the market now thinks SAGE-217 could become the first oral drug for postpartum depression, Marinus will probably need knockout data to attract a licensee.
Given the lack of clarity from Marinus, and the threat from Sage, perhaps focusing on epilepsy is a better bet.
MARINUSS TRIALS OF GANAXOLONE IN POSTPARTUM DEPRESSION
StudyDosingTrial IDData
Magnolia part 1IV (60 hours)NCT03228394Reported Dec 2018
Magnolia part 2Undisclosed IV to oralNCT03228394Topline, H1 2019
AmaryllisOral (undisclosed)NCT03460756Topline, H1 2019
Source: company presentation & clinicaltrials.gov.